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Treatments administered with more convenient devices such as DPIs and shorter 
administration times are associated with higher utility and higher stated adherence 
in adult and pediatric patients.
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Objectives: Fatigue is one of the most frequent symptoms in patients with 
multiple sclerosis (MS). This study aimed to examine the severity and impact 
of fatigue in MS Brazilian patients. MethOds: This was a cross-sectional, mul-
ticenter study conducted in 8 Brazilian major MS treatment sites. Fatigue was 
assessed using the Brazilian version of the Modified Fatigue Impact Scale (MFIS), 
which evaluates the impact of fatigue on 3 dimensions of patients’ daily life: 
physical, cognitive and psychosocial. The patient scores 0 (lower impact) to 84 
points (higher impact). The final score was classified according to the level of 
impact: absent (0-38), low (39-58), and high (> 58). Results: The study enrolled 
210 MS patients, of which the mean age was 40.7 [standard deviation = 11.5] years 
and 70.7% were female. Patients with mild disability (according to self-reported 
Expanded Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% 
had moderate disability and 15.9% had severe disability. In the overall sample, 
the impact of fatigue was considered absent, low and high in 49%, 32% and 19% 
of patients, respectively. Any impact (both low and high summed) was reported 
by 33%, 63%, and 66% of patients with mild, moderate and severe disability, 
respectively. The mean MFIS total score for mild, moderate and severe patients 
was 29.3, 45.0, and 45.4 (38.6 in the total sample). The mean impact scores for 
each domain in the total sample were 20.0 (physical, range 0-36), 14.7 (cogni-
tive, range 0-40), and 3.9 (psychosocial, range 0-8), meaning that fatigue has a 
proportionally higher impact in the physical than the cognitive or psychosocial 
domains. cOnclusiOns: Our findings indicate that over 50% of MS Brazilian 
patients notice some adverse impact of fatigue in their daily lives, particularly 
related to the physical domain.
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Objectives: To measure the health-related quality of life (HRQL) of multiple 
sclerosis (MS) patients and examine potential associations between HRQL and 
patients’ characteristics. MethOds: This was a cross-sectional, multicenter study 
conducted in 8 Brazilian major MS treatment sites. HRQL was assessed using the 
Brazilian version of the EQ-5D and patients self-evaluated their HRQL and health 
status using five dimensions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) and a visual analog scale (VAS). The EQ-5D index 
was calculated based on the value set derived from the UK population, since the 
Brazilian value set is not available. Results: The study enrolled 210 MS patients, 
of which the mean age (standard deviation [SD]) was 40.7 [11.5] years and 70.7% 
were female. Patients with mild disability (according to self-reported Expanded 
Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate 
disability and 15.9% had severe disability. Among the 5 assessed HRQL dimensions, 
the ones with higher frequency of self-reported severe limitations were usual 
activities and anxiety/depression (11.0% each). The least impaired dimension was 
self-care, with 63.0% of patients reporting absence of limitation. The mean [SD] VAS 
score was 71.6 [18.9]. The mean EQ-5D index for each level of EDSS (mild, moder-
ate or severe disability) was 0.73 [0.21], 0.49 [0.30], and 0.30 [0.34], respectively. 
In the multivariate analysis, variables related to patients’ characteristics were 
explored and the following were associated with the presence of any limitation 
in at least one dimension: older age, unemployment/retirement, relapses in the 
previous year, emergency department visits in the previous 6 months and lower 
educational level. cOnclusiOns: MS adversely impact patients’ HRQL, especially 
with disability progression and clinical features that can be linked to more severe 
disease.
Neurological DiSorDerS – Health care use & Policy Studies
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Objectives: To conduct a systematic review of literature in peer-reviewed jour-
nals on real world treatment patterns and clinical trials on patients diagnosed 
with Insomnia. MethOds: A comprehensive literature search was performed 
using relevant search terms to identify articles published from 2000 to 2010 on 
the real world treatment patterns and clinical trials conducted on patients with 
Insomnia. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human sub-
jects. Results: Our search yielded 1,153 articles for treatment patterns and clini-
cal trials on patients diagnosed with Insomnia from PubMed/Medline/Embase/
Cochrane databases. After removing duplicates and non-relevant articles, 65 
articles were included for final review. A total of 16 studies had some focus on 
44mcg was chosen as comparator since it is the most widely prescribed disease 
modifying therapy for 1st-line treatment in HARRMS patients in Brazil. MethOds: 
We developed a Markov model with 20-year time horizon comparing natalizumab 
to IFNB1a 44mcg. Health states were based on EDSS and relapses (moderate or 
severe). Since there are no published data evaluating long-term course specifically 
in HARRMS, we assumed transition probabilities on EDSS states based on natural 
history studies on unselected RRMS patients, and relapse probabilities based on 
a post-hoc analysis of the pivotal natalizumab AFFIRM trial. This is a rather con-
servative approach, since disability progression may be slower in this proposed 
model then expected for patients with HARRMS and so the benefit from natali-
zumab could be underappreciated. In each monthly cycle, patients can discontinue 
treatment, remain stable, progress to higher EDSS state, experience Progressive 
Multifocal Leukoencephalopathy or die. Patients with EDSS score≥ 7.5 receive best 
supportive care. Resource use and costs were validated by an expert’s panel and 
valued using Brazilian public official lists (DATASUS and BPS). Costs and outcomes 
were discounted (5%). Probabilistic sensitivity analyses (PSA) covered variability in 
efficacy and costs. Results: Use of natalizumab was associated with slower EDSS 
progression and reduced relapse burden. Life years gained with natalizumab and 
IFNB1a 44mcg were 10.90 and 10.54, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus IFNB1a 44mcg. 
PSA has confirmed the consistency of results. cOnclusiOns: For a patient with 
HARRMS, the model shows that natalizumab was dominant when compared to 
IFNB1a 44mcg in the Brazilian Public Healthcare System.
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Objectives: To assess the health care resource utilization (HRU) of Brazilian mul-
tiple sclerosis (MS) patients. MethOds: This was a cross-sectional, multicenter 
study conducted in 8 Brazilian major MS treatment sites. HRU was evaluated as 
the percentage of patients self-reporting the consumption of resources. The main 
categories were: hospitalization, consultations, laboratory and imaging tests, dis-
ease modifying therapies (DMTs), co-medication, aidsand/or home modifications. 
Frequency and average consumption were annualized. Results: The study enrolled 
210 MS patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% 
female. Patients with mild disability (according to self-reported Expanded Disability 
Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability 
and 15.9% had severe disability.Hospitalization was reported by 23%, 33% and 15% 
of mild, moderate and severe MS patients, with average length of stay of: 7.53, 10.41, 
and 7.40 days, respectively. Most patients (> 96%) had at least one neurologist con-
sultation per year (average 4.94 visits/year in the total sample). Physical therapy was 
the most consumed non-medical consultation (mild: 11%; moderate: 38%; severe: 
64%). Magnetic resonance imagingwas reported by 60%, 68%, and 55% of mild, mod-
erate and severe patients. Patients using at least one DMT during the previous year 
were: 89%, 93%, and 61% of mild, moderate and severe MS patients, respectively. 
The most prescribed DMT was glatiramer acetate (38%, total sample). The most fre-
quent co-medications were: anti-depressants, anti-spasticity, and analgesics. Home 
modification was reported by 19% and 45% of patients with moderate and severe 
disability, respectively. For ambulation, walking stick was used by 35% of moderate 
patients, while wheelchair was needed by 58% of severe patients. cOnclusiOns: To 
our knowledge, this is the first Brazilian study investigating the HRU of MS patients. 
The findings can be useful to better understand MS patients’ needs in terms of 
comprehensive care.
Neurological DiSorDerS – Patient-reported outcomes & Patient Preference 
Studies
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Objectives: To quantify patient and parent preferences and adherence for dif-
ferent administration features of inhaled antibiotic medicines for cystic fibrosis 
(CF). MethOds: Adult patients with a self-reported physician diagnosis of CF and 
parents of pediatric CF patients (6 to 17 years) who had Pseudomonas aeruginosa in 
their lung culture at least twice in one year completed a web-enabled, discrete-
choice experiment survey in the United States. Respondents answered 5 treat-
ment-choice questions with known statistical properties. Each question required 
evaluating a pair of hypothetical CF treatment profiles defined by device type (nebu-
lizer, dry powder inhaler (DPI)), total daily administration and cleaning time, dosing 
frequency, dry cough side effect, and personal cost per cycle. Lung function meas-
ured as forced expiratory volume in one second (FEV1) was held constant between 
the hypothetical CF treatment profiles. Stated adherence questions followed two 
randomly selected treatment-choice questions. Random-parameters logit models 
were used to estimate preference weights for all feature levels and the mean rela-
tive importance of each feature for both samples. Results: A total of 209 adult 
patients and 271 parents completed the survey. Mean age of adult patients was 32 
(SD = 10) years and mean age of pediatric patients was 12 (SD = 3) years. Among 
all respondents, the average time spent taking inhaled antibiotic medicines was 
approximately 40 minutes. Relative importance estimates indicated that switching 
from a 30-minute nebulizer twice daily to a 10-minute DPI twice daily was 6.3 times 
more important for adult patients and 2.0 times more important for parents than an 
improvement in dry cough from moderate to mild. Stated adherence for adult and 
pediatric patients was 20-30% higher for DPIs versus nebulizers. cOnclusiOns: 
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hospitalar e custo do procedimento. MétOdOs: A partir do sistema de faturamento 
do HIAE foram selecionados 538 procedimentos de septoplastia com turbinecto-
mia e sinusectomia realizados no ano de 2011 que utilizaram as técnicas com-
paradas neste estudo. Foram incluídos na análise 517 pacientes, 56 procedimentos 
utilizando o microdebridador e 461 utilizando a técnica convencional. Em média, 
os pacientes que utilizaram o microdebridador possuíam uma faixa etária mais 
elevada e um percentual maior dos pacientes apresentaram diagnóstico de sinusite 
crônica. ResultAdOs: Em relação à média de tempo de permanência hospitalar 
esta foi maior no grupo do microdebridador (28 horas versus 22 horas no grupo 
da técnica convencional, p= 0,002). A quantidade média de unidades de cola e de 
hemostático foi maior no grupo que utilizou o microdebridador. Não houve difer-
ença estatística entre os grupos nos desfechos de tempo de cirurgia e nas taxas de 
readmissão hospitalar. No desfecho de dor no pós operatório imediato a diferença 
entre os grupos foi estatisticamente significativa (p = 0,006), indicando um per-
centual maior de pacientes com escore de dor acima de 5 sendo tratados com o 
microdebridador, quando comparado com o grupo convencional. Considerando-se 
o custo do procedimento com a técnica convencional como referência, o uso do 
microdebridador resultou em um aumento médio de 17,4% em relação à técnica 
convencional. cOnclusões: O uso do microdebridador não se mostrou favorável 
nos desfechos avaliados, tendo em vista um aumento do tempo de permanência do 
paciente, uso de colas e hemostáticos em maior quantidade que a técnica conven-
cional e o custo do procedimento foi significativamente mais alto.
PrS5
coMPariNg coPD coStS By exacerBatioN freQueNcy aND DySPNoea 
level iN a PriMary care SettiNg iN tHe uNiteD KiNgDoM
Punekar Y.S.1, Shukla A.2, Muellerova H.3
1GlaxoSmithKline, Uxbridge, UK, 2GlaxoSmithKline, Upper Providence, PA, USA, 3GlaxoSmithKline 
R&D, Uxbridge, UK
Objectives: Economic burden in Chronic Obstructive Pulmonary Disease (COPD) 
patients with varying levels of dyspnoea is largely unknown. The objective of this 
retrospective analysis was to estimate the resource use and the associated costs 
incurred by COPD patients with increasing levels of dyspnoea with or without fre-
quent exacerbations. MethOds: A retrospective cohort of prevalent COPD patients 
was identified in the Clinical Practice Research Datalink (CPRD). All patients who had 
at least 12 month pre- and post- cohort entry date (1st prevalent COPD diagnosis 
confirmed by spirometry ≥ April 1, 2009) recorded were included in the analysis. 
Patients were categorised as having none, 1 or 2+ exacerbations in the 12 months 
post cohort entry and further classified using Medical Research Council (MRC) dysp-
noea scale. Study outcomes included general practitioner (GP) visits, community 
treated exacerbations (medical dg for exacerbation or ATB+OCS Rx), hospital treated 
exacerbations and all-cause hospitalisations excluding COPD exacerbations. The 
costs associated with the estimated resource use were calculated using National 
Health Service (NHS) reference costs for 2010-11. Results: The cohort consisted 
of 51,641 COPD patients with 27,764 (53.8%), 12,585 (24.4%) and 11,292 (21.9%) hav-
ing experienced none, 1 and 2+ annual exacerbations post cohort entry. Among all 
patients, the estimated annual COPD management costs, excluding the costs of 
medications, were £1,597, £1,849, £2,298, £2,745 and £3,579 with increasing levels 
of dyspnoea (MRC grade 1-5). The equivalent cost ranges by exacerbation frequency 
were £1,267-£2,235, £2,021-£3,447 and £2,627-£4,709 for patients with none, 1 or 2+ 
annual exacerbations, respectively. cOnclusiOns: Increase in COPD management 
costs with increase in level of dyspnoea occurred in all exacerbation frequency 
groups. Better symptom control and disease management strategies in primary 
care setting may help reduce COPD costs significantly.
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Objectives: Smoking is the single most preventable cause of disease and death all 
around the world. Our objective was to quantify the disease burden associated with 
smoking in Argentina, Bolivia, Brazil, Chile, Colombia, Mexico and Peru. MethOds: 
The project began with a survey to health Decision Makers (DM) to explore country-
specific information needs. The development stage involved the harmonization of 
a methodology to retrieve local relevant parameters and develop the model struc-
ture. A microsimulation HEM was built considering the availability and quality of 
epidemiological data and relevant outcomes were conceived to suit the identified 
information needs of DMs . It considers all tobacco-related diseases: heart, cerebro-
vascular and chronic obstructive pulmonary disease, pneumonia/influenza, lung 
cancer and nine other neoplasms. A systematic search on effectiveness, local epide-
miology and costs studies was undertaken to populate the model. Calibration and 
validation was performed for each country. Predicted event rates were compared 
to the published rates used as model inputs. External validation was undertaken 
against epidemiological studies not used to provide input data. Results: The cali-
brated model showed all simulated event rates falling within ±10% of the sources 
and a high correlation between published data and model results. In these seven LA 
countries, tobacco is responsible of 259,126 deaths each year. The diseases attrib-
utable to smoking cause a total of 1∙90 million years of life lost due to premature 
death, 0∙64 million years of life lost due to disability and at least 27 billion dollars 
(USD dollars 2013) in direct medical costs each year. cOnclusiOns: Tobacco use is 
real world treatment patterns in Insomnia patients and majority of these stud-
ies focused on benzodiazepine users. The rate of medication use in Insomnia 
patients is fairly low and rates were ranging from 17% to 75%. There were a total 
of 11 trials published testing Eszopiclone use, 10 trials each on Ramelteon and 
Zolpidem, 4 trials on Indiplon, 3 trials on Gaboxadol, 3 trials on Doxepin use in 
patients diagnosed with Insomnia. Several patient reported outcomes measures 
were used in the assessment of various clinical trials. cOnclusiOns: There 
were a variety of agents being used to treat insomnia; while benzodiazepines 
and non-benzodiazepines were largely popular. Products in development need to 
be studied further to determine whether their new mechanisms of action were 
truly beneficial for treatment.
reSPiratory-relateD DiSorDerS – clinical outcomes Studies
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Objectives: To investigate the patient’s acute asthma characteristics, and iden-
tify predictors of asthma control in a population of asthma patients from five 
Latin American countries. MethOds: Adults and parents of adolescents (12-17 
years) with a physician diagnosed asthma and asthma medication use or asthma 
attacks in the past year were surveyed as part of the 2011 Latin America Asthma 
Insights and Management (AIM) survey. Using Global Initiative for Asthma (GINA) 
guidelines as a reference, respondents were categorized into three levels of asthma 
control: well-controlled, partly- controlled, and uncontrolled. Chi-square tests 
and adjusted logistic regression were used to determine odds ratios (ORs) to 
assess the relation of degree of asthma control with frequency of sudden asthma 
episodes, frequency of asthma symptoms, duration of episodes, day-and night 
time symptoms, utilization of rescue medications, and asthma episodes season-
ality. Results: Data from 2168 adults and parents from asthma patients ≥ 12 
years survey was analyzed. Seven percent (7%) of the patients are controlled, 57% 
partially controlled, and 36% uncontrolled. Adjusted logistic regression models 
showed that patients whose asthma was uncontrolled were significantly more 
likely to have acute sudden asthma episodes compared to patients whose asthma 
was controlled either partially or fully. Similarly, patients with uncontrolled 
asthma were significantly more likely to have higher frequency of asthma episodes 
in most days of the week, increased day and night symptoms than those asthmat-
ics who were controlled cOnclusiOns: Patients who did not have well-controlled 
asthma had more acute episodes as compared to patients whose asthma was 
well-controlled. Our results strongly suggest that the acute asthma requires a 
significant effort to decrease its severity.
PrS3
graPHic HealtH warNiNgS oN cigarette PacKS iN Qatar: Pre-
iMPleMeNtatioN awareNeSS aND PercePtioN aMoNg tHe geNeral 
PuBlic
Awaisu A., Hagi A., Ashour M.A., Kheir A.N.
Qatar University, Doha, Qatar
Objectives: Graphic health warnings (GHWs) on cigarette packages have been 
found to be significantly associated with increased awareness of smoking-related 
health hazards as well as behavior change. Legislations on GHWs have recently 
been endorsed and GHWs have now been introduced in Qatar. This study aims to 
evaluate the general public’s awareness, beliefs and perceptions on anti-tobacco 
GHW labels on cigarette packs prior to the introduction of the new law. MethOds: 
A cross-sectional survey using a pretested 23-item questionnaire was conducted 
among randomly approached adults in Qatar. Data were analyzed using the IBM 
SPSS® version 19. Responses were analyzed by smoking status (ever-smokers 
vs. never-smokers) to ascertain how these two distinct groups differed in their 
awareness and perceptions related to health warning messages. The demographic 
characteristics and other outcomes of interest were compared using χ 2 or Fishers 
Exact tests. Results: A total of 500 participants (59% male) responded to the sur-
vey. Most notably, ever-smokers did not significantly differ from never-smokers 
on awareness of GHW. About one-third of the respondents had no idea about any 
specific text warning messages on tobacco products sold and nearly 45% of them 
did not know what a GHW was. Furthermore, a substantial proportion (more than 
20%) of the respondents in both groups did not believe that introducing GHWs 
will enhance smoking behavior change. Non-smokers generally tended to have 
more positive attitudes than smokers toward the perceived impact of GHWs (p < 
0.05). cOnclusiOns: A substantial proportion of the general public in Qatar had 
poor awareness about GHWs. This study has important implications on the needs 
to increase awareness about the value of GHWs as well as calls for further research 
to determine the effectiveness of GHW labels on cigarette packages in Qatar and 
the greater Middle Eastern region, where legislations on GHWs are still at infancy.
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ObjetivOs: O objetivo deste estudo foi comparar as técnicas cirúrgicas com uso 
do microdebridador em relação à técnica convencional nos procedimentos de sep-
toplastia com turbinectomia e sinusectomia, quanto ao tempo de cirurgia, tempo 
de hospitalização, uso de colas e hemostáticos, escore de dor, taxa de readmissão 
